| abstract |
The present invention relates to a polypeptide comprising human IL-2-mutein numbered in accordance with wild-type IL-2, wherein human IL-2 is substituted in at least one of sites 20, 88 or 126, with the mutein being preferably activated T cells in front of NK cells. D20H and I, N88G, I and R in particular have relative T-cell differential activity much higher than native IL-2 with the predicted combined reduced toxicity in vivo. The present invention also includes polynucleotides encoding the muteins of the invention, vectors containing polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins and therapeutic treatments. |